Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Once-per-cycle DA-3031 (PEG-G-CSF) vs Daily G-CSF for Chemotherapy-induced Neutropenia
KCT0000518Phase 3Completed
- Sponsor
- Dong-A Pharmaceutical
- Start
- Feb 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegteograstim in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Dong-A Pharmaceutical. Primary endpoints: Efficacy in chemotherapy-induced neutropenia and Safety. Started Feb 2012; status: completed.
02
Drugs
pegteograstim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on KCT0000518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000518.